Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary

October 29, 2026

New York Stock Exchange US Health Care Pharmaceuticals earnings

What were the key takeaways from Merck & Co., Inc.'s October 29, 2026 earnings call?

In the third quarter of 2026, Merck & Co., Inc. reported revenues of $18.1 billion, reflecting a 5% increase year-over-year, driven by strong contributions from new products and oncology. The company achieved earnings per share (EPS) of $2.49, which includes a $0.12 charge related to a license agreement. Management raised the midpoint of their full-year revenue and EPS guidance, now expecting revenue between $66.8 billion and $67.3 billion and EPS of $2.77 to $2.82, signaling confidence in their expanding pipeline and product launches.

What topics did Merck & Co., Inc. cover?

  • Revenue Growth: Merck reported third-quarter revenues of $18.1 billion, a 5% increase year-over-year, with oncology sales contributing significantly. CEO Rob Davis stated, "We're executing well on all fronts, demonstrated particularly by the many new product launches now successfully underway."
  • KEYTRUDA Performance: Sales of the KEYTRUDA family increased 6% to $8.6 billion, driven by strong demand in earlier-stage cancers. Caroline Litchfield noted, "We continue to see adoption increase, which supports our confidence in the trajectory of the product."
  • Guidance Update: Management raised the midpoint of their full-year guidance, now expecting revenue between $66.8 billion and $67.3 billion. Caroline Litchfield stated, "We have narrowed the range and raised the midpoint of both our full year revenue and EPS guidance."
  • Clinical Milestones: Merck achieved several important clinical milestones, particularly in oncology, with positive Phase III results for sac-TMT in endometrial cancer. Dean Li highlighted, "We look forward to continuing to work with the FDA to deliver this potential new option as quickly as possible."
  • Pipeline Confidence: Management expressed confidence in their pipeline's ability to drive long-term growth beyond the KEYTRUDA LOE period. Rob Davis remarked, "The opportunity we have to drive strong long-term growth beyond the KEYTRUDA LOE period is becoming increasingly clear."

What were Merck & Co., Inc.'s October 29, 2026 results?

  • Revenue: $18.1 billion
  • EPS: $2.49 (includes a charge of $0.12 per share related to the SciBrunch license agreement)
  • GARDASIL Sales: $2 billion (+14% YoY)
  • WINREVAIR Sales: $694 million (+94% YoY)
  • Operating Expenses: $7.4 billion (+12% YoY)
  • Gross Margin: 81.4% (decreased slightly)

Merck's strong third-quarter results and raised guidance reflect solid operational execution and confidence in their pipeline. However, the anticipated challenges from generic competition and pricing dynamics could pose risks to future growth. Investors should monitor the progress of new product launches and clinical milestones as potential catalysts.

Earnings Call Speaker Segments

Peter Dannenbaum

executive
#1

Appreciate that, Julie, and hello everyone on the line. We're glad to have you with us for the Third Quarter 2026 Conference Call of Merck & Co., Inc., headquartered in Rahway, New Jersey, USA. With us today are Rob Davis, our Chairman and Chief Executive Officer; Caroline Litchfield, our Chief Financial Officer; and Dr. Dean Li, President of Research Labs. Ahead of getting started, please keep in mind that our GAAP figures contain things such as acquisition-related charges, restructuring costs, and certain other items — every one of which has been left out of our non-GAAP results. You'll find a reconciliation in our press release. I also want to remind everyone that some of what we say today might count as forward-looking statements under the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Such statements represent the current beliefs of the company's management and come with substantial risks and uncertainties. If our underlying assumptions turn out to be inaccurate or uncertainties come to pass, actual results could differ materially from those described in the forward-looking statements. Our SEC filings, including Item 1A in the 2025 10-K, identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any forward-looking statements we make this morning. Merck & Co., Inc. Rahway, New Jersey-based company in the United States accepts no duty to revise forward-looking statements publicly. A slide deck will go with our speakers' ready comments on today's call. Those slides, plus the earnings release, the remarks prepared for today, and our SEC filings, all appear in the Investor Relations area of our corporate site. On that note, I'll hand things over to Rob.

Robert Davis

executive
#2

Thank you, Peter. Good morning, and thanks for being with us on today's call. For our company, 2026 remains a year in which we are making substantial progress. We're executing well across every front, and that shows especially in the many new product launches that are now successfully underway, along with the important clinical milestones we're reaching that continue to reduce the risk attached to the considerable long-term opportunity in our late-phase pipeline. This momentum carries across numerous therapeutic areas and modalities, and plenty more is still ahead, with many significant readouts yet to come in the years to follow. I'm very pleased that our disciplined execution of strategy over the past several years is increasingly turning into meaningful clinical, regulatory and commercial results. The breadth of these achievements leaves me more confident about our company's future and about our capacity to deliver long-term value to patients and shareholders. Now to our third quarter results. We posted solid performance, with revenue of $18.1 billion, reflecting growing contributions from new products along with strength in oncology and animal health. Caroline will go into our results and the full year outlook in greater detail shortly; we also hit several important clinical and regulatory milestones; in oncology, last weekend's ESMO meeting displayed potential practice-changing advances across several innovative programs, led by the first positive Phase III results from our expansive global TroFuse program for sac-TMT in advanced or recurrent endometrial cancer. Further data shared at that meeting by our partner, Kelun, add support for sac-TMT's potential in lung cancer and other tumor types; and we're encouraged by the landmark validation of a therapeutic cancer vaccine, with positive Phase III data presented for intismeran autogene as an adjuvant treatment for certain patients with melanoma. This new approach may present a tangible opportunity to alter the trajectory of a patient's cancer; in ophthalmology, we presented results from the BRUNELLO study evaluating remigromig in diabetic macular edema, a significant milestone for our retinal disease portfolio, which is advancing rapidly. And finally, in immunology, we presented encouraging Phase IIb results in HS and look forward to moving our TL1A development program ahead; this year's clinical and commercial progress underscores the ongoing transformation of our business and gives us greater visibility into the trajectory of our emerging and expansive new product portfolio. The opportunity before us to drive strong long-term growth beyond the KEYTRUDA LOE period is becoming increasingly clear as we reach these scientific and commercial milestones. Looking ahead, we'll stay focused on executing our launches successfully, broadening and advancing our pipeline and making meaningful investments so these opportunities reach their full potential. I want to recognize and thank our dedicated global teams for their ongoing commitment to delivering value for patients, shareholders and all of our stakeholders. And now I'll hand the call over to Caroline.

Caroline Litchfield

executive
#3

Appreciate that, Rob, and good morning everyone. As Rob noted, we delivered a strong quarter, helped by rising contributions from our impressive roster of significant new products, along with ongoing momentum in oncology and Animal Health. Robust commercial and operational performance continues to propel our near-term results, even while we invest to fine-tune our launches and advance our broad, deep pipeline to generate long-term value for patients, customers, and shareholders. Moving now to our third quarter results: total company revenues reached $18.1 billion, an increase of 5%, or 4% when excluding the impact of foreign exchange. The revenue commentary that follows will be on an ex-exchange basis. Within oncology, the KEYTRUDA franchise — that is, KEYTRUDA together with KEYTRUDA QLEX — rose 6% to reach $8.6 billion. Worldwide gains came from robust adoption in earlier-stage cancers as well as continued strong demand throughout metastatic indications. Key contributors to that growth included solid use in tumors predominantly affecting women, particularly cervical and breast cancers, along with expanded use of KEYTRUDA in combination with PADCEV for urothelial cancer. We also observed ongoing adoption in earlier-stage head and neck cancer. As anticipated, the timing of U.S. customer purchases in the prior year generated a growth headwind, though an increase in channel inventory largely offset it, and we expect that inventory to unwind during the fourth quarter. Sales of KEYTRUDA QLEX were $830 million. Adoption keeps rising, and that reinforces our belief in how this product is tracking. Turning to the wider oncology lineup, WELIREG brought in $307 million, up 58%, fueled by greater use in previously treated patients and as adjuvant therapy for specific renal cell carcinoma patients in the U.S., along with continued uptake from ongoing launches abroad. On the vaccines and infectious diseases side, GARDASIL posted $2 billion, a 14% gain. U.S. sales climbed 18%, helped by a sizable CDC purchase and pricing, while international markets rose 6%. For pneumococcal, CAPFEXYV came in at $263 million, up 7%, powered by ongoing launches in certain international markets. U.S. revenue fell 13%, since gains in market share were outweighed by reduced adult pneumococcal vaccination uptake; for RSV, Influenza, the $187 million in sales mirrors seasonal demand along with related inventory building. Within Cardiometabolic and Respiratory, WINREVAIR kept up its momentum, posting worldwide sales of $694 million — a 94% rise — driven by robust demand among adults suffering from pulmonary arterial hypertension plus a boost from channel inventory. In the U.S., roughly 1,600 new patients got a prescription, and about 30% of them were receiving background therapies that excluded a prostacyclin. Beyond the U.S., launches already underway keep moving forward. OHTUVAYRE generated $184 million in revenue, supported by ongoing demand from adults with COPD, although that was partially countered by a slight headwind tied to the timing of specialty pharmacy purchases. While it's still early, the first rollout of LIPFENDRA leaves us encouraged. Both prescription patterns and physician feedback have been favorable. We've additionally established programs aimed at supporting access and affordability for patients who qualify. As anticipated, creating widespread access will require time, and our confidence in the long-term opportunity for this important treatment option for adults with elevated LDL cholesterol stays strong. Our Animal Health business posted 3% growth. Companion animal sales rose 6%, fueled by new product launches. Poultry demand came in stronger, lifting livestock sales by 2%. Now for the rest of our P&L, and here I'll be referring to non-GAAP numbers. Our gross margin dipped slightly to 81.4%. Operating expenses were up 12%, hitting $7.4 billion — that reflects stepped-up investment behind our launches and advancing the wide pipeline we have in both early and late stages; the increase was partly offset by savings from the multiyear optimization effort underway and by recognizing a portion of the external funding for SECTMT development. In addition, we booked a $400 million upfront charge tied to the license agreement with SciBrunch, versus a $300 million business development charge a year earlier. Other expense rose to $420 million, mostly because of financing costs tied to recent business development deals. Our tax rate came in at 10.9%, reflecting a benefit from certain discrete items. All told, earnings per share were $2.49, and that number includes a $0.12 per share charge related to the SciBrunch license agreement. Turning to our 2026 non-GAAP guidance: we've narrowed the range and raised the midpoint for both full year revenue and EPS guidance. Revenue is now expected to land between $66.8 billion and $67.3 billion, which works out to growth of 3% to 4%, and that includes a positive foreign exchange impact of roughly 1 percentage point based on mid-October rates. Our gross margin estimate remains around 81%, while operating costs are expected to land somewhere from $42.4 billion to $42.9 billion. Other expense is still projected at approximately $1.4 billion. For the entire year, we now expect a tax rate between 32% and 33%. We're basing this on roughly 2.48 billion shares outstanding. Putting all those pieces together, we anticipate EPS of $2.77 to $2.82, and that figure includes an estimated $0.15 benefit from foreign exchange using mid-October rates; the SciBrunch charge is factored into that same range as well. As you build out your models, a few points are worth keeping in mind. In Q3, sales got a lift of roughly $550 million because of favorable purchase timing in the U.S. We anticipate that the gain tied to KEYTRUDA and WINREVAIR will completely reverse in Q4, while most of the benefit to vaccines—mainly GARDASIL—should reverse next year. Looking ahead to 2027, we recently indicated we expect modest revenue growth. With KEYTRUDA, slower growth mirrors how well we've done at reaching eligible patients, since we're now nearing peak revenues for some approved indications. We also anticipate policy dynamics will affect the German market. For BRIDION, we expect competition from several generics that have now launched. On vaccines, we're monitoring wider market patterns in light of greater hesitancy and lower utilization. Also, for underlying operating expenses, we're looking at growth in the mid- to high single digits, and that mirrors how confident we are in the sizable opportunity coming from a pipeline that keeps getting bigger and a growing lineup of new product launches. Now, on capital allocation, what we prioritize hasn't changed. We'll keep steering money toward opportunities that create value and fuel growth both near term and long term. Our commitment to the dividend is the same as before, and the aim is to raise it over time. Growing the business is still a top priority, and our investment-grade credit rating—a strong one—gives us the financial flexibility to continue pursuing more transactions that are science-driven and add value. We remain on course to repurchase approximately $3 billion of shares this year. To wrap up, our confidence in the outlook for the business is solid as we head into the fourth quarter. Demand continues to be robust throughout our varied portfolio of human and animal health products, and our newer launches are adding to growth in a way that is increasingly significant. The strong, creative set of assets we have in development continues to move forward, and that puts us in a great spot to create exceptional value for patients, customers and shareholders today and going forward. With that said, I'll turn the call over to Dean.

Dean Li

executive
#4

Thank you, Caroline, and good morning to everyone. During the third quarter we saw several important clinical and regulatory milestones. In my remarks today, I'll give updates across oncology, cardiometabolic and respiratory, immunology and ophthalmology. Then I'll finish by pointing to milestones that lie ahead. Beginning with oncology — as Rob mentioned, data from multiple pivotal studies were presented at ESMO, and those data illustrate how we approach clinical development and show how KEYTRUDA is helping shape progress across our pipeline. At ESMO we presented for the first time detailed Phase III findings from our broad global TroFuse development program for sac-TMT, our TROP2-directed ADC that carries a unique bifunctional linker. A two-pronged development strategy guides the TroFuse program. To start, we're aiming to be an early leader in several diseases and treatment settings, and we're doing it both quickly and carefully. Several of these first-mover chances are in gynecologic cancers, where the unmet need is still significant. At ESMO, the TroFuse-005 trial assessed sac-TMT in endometrial cancer patients whose disease had worsened following platinum chemotherapy and anti-PD-1-L1 immunotherapy, and it demonstrated a striking gain of almost 7 months in median overall survival compared with chemotherapy by itself. Endometrial cancer is one of the few cancers with incidence and mortality rates climbing across the globe. Right now these patients face a very poor prognosis, and we're eager to keep working with the FDA so this potential new option can get to them as fast as possible. Second, we're looking at where sac-TMT might stand apart in particular breast and lung cancer cases. In the first-line setting for PD-L1 negative non-squamous non-small cell lung cancer, the OptiTROP-Lung06 trial conducted by our partner Keelin demonstrated a meaningful gain in progression-free survival when sac-TMT was combined with KEYTRUDA versus KEYTRUDA plus chemotherapy — suggesting that new combination approaches could surpass the demanding benchmark established by KEYTRUDA plus chemotherapy. Across a range of non-small cell lung cancer settings, our Global TroFuse program currently encompasses 5 Phase III studies; in first-line non-small cell lung cancer, we intend to study sac-TMT paired with MK-2010, our PD-1 VEGF bispecific. Our interactions with the FDA have been fruitful, and we expect Phase III trials in this indication to begin in the first half of 2027. Moving on to intismeran, our thorough grasp of tumor biology keeps shaping the following generation of our oncology pipeline, which includes work on an mRNA therapeutic cancer vaccine built around each patient's tumor's distinct mutational signature. At ESMO, we unveiled pivotal data for intismeran — an investigational individualized neoantigen therapy created alongside Moderna and combined with KEYTRUDA as adjuvant treatment for melanoma. The INTerpath-001 trial's findings showed clinically meaningful gains in recurrence-free survival and distant metastasis-free survival when intismeran plus KEYTRUDA was compared with the standard of care, KEYTRUDA, among patients whose Stage IIb/IIV melanoma had been completely resected. These findings, which add to the evidence base established by the Phase IIb trial, give us greater confidence that intismeran combined with KEYTRUDA may offer curative benefit; we are in active discussions with the FDA regarding a regulatory submission. Beyond that, we are moving forward an extensive INTerpath clinical development program spanning multiple immune-sensitive tumors, among them indications at earlier disease stages where KEYTRUDA has already demonstrated efficacy. Phase III trials are ongoing in melanoma and non-small cell lung cancer, both marked by high mutational burden. Additional Phase II studies are evaluating tumors with lower mutational burden, such as certain bladder and renal cancers, to help guide possible future expansion. I'm eager to provide additional updates on these programs and others in oncology. Turning to some regulatory news: regulatory authorities in Japan and China have approved subcutaneous pembrolizumab and berahyaluronidase alfa. In Europe, we received approval for KEYTRUDA combined with PADCEV as a perioperative treatment for resectable muscle invasive bladder cancer; and the FDA in the U.S. approved WELIREG plus LENVIMA for patients with previously treated renal cell carcinoma. Regarding ifinatamab deruxtecan, we and Daiichi Sankyo have chosen to withdraw the biologic license application that sought accelerated approval. Numerous I-DXd studies continue in small cell lung cancer, prostate cancer and other tumor types. Moving on to cardiometabolic and respiratory: WINREVAIR's label update was recently approved by the FDA. It now includes data from the Phase III HYPERION study, which adds further support for using the drug earlier in treatment for adults who have pulmonary arterial hypertension. With WINREVAIR, we brought forward activin signaling inhibition — a new mechanism aimed at the vascular remodeling underneath disease progression. Building on what the Phase II CADENCE trial showed, we're taking a significant step toward extending activin signaling inhibition's use past Group 1 PAH. In the coming Phase III CORE study, patients will be evaluated who have combined post- and pre-capillary pulmonary hypertension tied to heart failure with preserved ejection fraction. This subgroup of Group I pulmonary hypertension shares vascular features with PAH, and there are no approved treatments for it at present. Now turning to immunology. At EADV last month, positive Phase IIb data were shared for tulisokibart in hidradenitis suppurativa patients — the first anti-TL1A antibody to show positive clinical results in a dermatology indication. The trial showed encouraging clinical responses along with a promising safety profile. With these results in hand, we intend to move tulisokibart into Phase III development for HS. And last, ophthalmology: as Rob noted, earlier this month we presented findings from the Phase IIb/III BRUNELLO study, which is the first of two pivotal trials of remigromig, a novel Wnt agonist, in adults with DME. On the call, we noted that Brunello met its primary endpoint at both monthly remigromig doses. At one year, the data showed non-inferior best corrected visual acuity versus monthly ranibizumab 0.5 milligram. Anti-VEGF treatments have changed how DME is managed, yet many patients still have active disease, which underscores the demand for new therapeutic choices. Bruno offers clinical evidence that activating the Wnt pathway can deliver efficacy non-inferior to an anti-VEGF agent in DME. If the companion BRUNELLO trial confirms this, remigromig could introduce a promising new mechanism that acts orthogonally, helping move ophthalmology toward therapeutic approaches involving multiple pathways. To wrap up, the scope of these milestones shows how far we've come in turning fresh insights into disease biology into medicines that could matter significantly across a range of therapeutic areas. Across the coming 12 months, we expect a number of key clinical and regulatory milestones, among them in immunology, where for tulisokibart we are putting together data from the Phase III ATLAS-UC study and look forward to sharing those results in the near term. Moving to ophthalmology, we have the readout from the BAROLO study of remigromig. In cardiometabolic and respiratory, there's the launch of the Phase III CORE study in infectious disease, along with anticipated regulatory filings for islatravir plus lenacapavir—potentially the first once-weekly oral two-drug HIV treatment regimen. We also expect data from the Phase III ANCHOR study evaluating MK-1406, our investigational long-acting, strain-agnostic antiviral intended to prevent influenza, as well as data from the Phase III express program for alimatravir, our investigational once-monthly oral HIV PrEP option. Finally, in oncology, there's the potential approval of sac-TMT in endometrial cancer and further Phase III readouts, the anticipated regulatory filing of intismeran, and additional readouts across multiple other programs. With that, I'll hand the call back to Peter.

Peter Dannenbaum

executive
#5

Thanks, Dean. Before we begin the Q&A, I’m really glad to welcome Jannie Oosthuizen and Brian Foard, who are joining us this morning to help take questions; and just to remind everyone, Jannie is President of our Oncology business unit and also of MSD International, while Brian is President of our Specialty Pharma and Infectious Diseases business unit. I’d also ask that analysts please stick to one question each today, so we can reach as many people as possible within the time available; so Julie, please go ahead and open the Q&A. Thank you.

Chris Schott

analyst
#6

Congratulations on everything you've achieved so far. So I suppose what I want to ask — you made some remarks recently about 2027, on both the top line and spending; and this may be a two-part question. What I'd like to know is whether you believe that is now properly captured in consensus estimates. And then, given the R&D spending we're seeing from the company in the near term, plus the longer-term pipeline derisking that we've witnessed, is it fair at this point to think about earnings growing from this kind of level as we move through the KEYTRUDA LOE — put another way, does this R&D spend essentially pull your trough earnings forward, so that we can think more about earnings growth for Merck as we look out to the 2030s?

Caroline Litchfield

executive
#7

Chris, thanks for asking. First, let me perhaps give everyone the headlines regarding what we said about 2027, and then I'll address the specific questions. We view 2027 as yet another year of investment, as we put money behind our expansive pipeline and our new product launches to drive long-term growth. To be specific about 2027, we anticipate moderate top line growth, and that reflects the strong contributions we expect from our new product launches as well as Animal Health, which will be partly offset by more than $2 billion of headwinds stemming from generic competition and LOE affecting BRIDION, the JANUVIA family of products, as well as Adempus. We do expect KEYTRUDA to remain an important contributor to our overall revenues, though we do see growth moderating, and that's because we've reached peak penetration in a number of indications. We also expect headwinds to price in our ex-U.S. market, and we're watching the policy dynamics in Germany. On the vaccines side, we saw a benefit from a CDC buy-in in 2026 of approximately $250 million that will unwind in 2027. Now, looking at the rest of the P&L, gross margin will rise given the roll-off of a royalty on KEYTRUDA. As you noted, we expect expenses to go up because we are fully investing behind our strong pipeline as well as our launches; and we do expect slightly higher interest expense and a slightly higher tax rate. But overall, '27 represents a year of investment for strong growth in our future, which is all part of driving our strategy for how our company grows beyond the KEYTRUDA LOE. Now, as we look at that, we see the KEYTRUDA LOE as really more of a hill on our company's overall revenues, as we will, in short order, then return to strong growth. When we look at consensus estimates for 2027, there are a number of different estimates among the different analysts, and some have incorporated the messaging that we've given, while many have not yet. Hopefully that makes clear what we expect for 2027. As we look at earnings going forward, we do expect our company's earnings to grow as we approach the LOE period. As I mentioned, we do expect a shallow dip in revenues during the initial period after price setting through IRA and the LOE, but we expect a quick return to growth. And we would expect the earnings profile to probably mirror that, given the expansive pipeline we have, the continued studies we will be doing and supporting, and the launches coming through year-over-year. So, headline: we are confident in our future and in our pipeline, which will drive long-term growth and patient benefit and enable us to offset the KEYTRUDA LOE over time.

Peter Dannenbaum

executive
#8

Great. Thank you, Chris. Next question please, Julie.

Vamil Divan

analyst
#9

Great to hear the pipeline is moving along so well. Maybe just a couple of questions on WINREVAIR, if that's alright. First off, can you give us a quick number for the one-time benefit you saw tied specifically to WINREVAIR in this quarter? I realize you bundled it into that $550 million figure for the pharma business overall. Then, Dean, I'd like to ask you specifically about the CORIST trial; we did see it listed on clinical. Could you walk us through how it stacks up against, or differs from, what you ran in the Phase II CADENCE trial—on the endpoint, on the inclusion criteria—just so we get a feel for how the patients and the study will line up against each other.

Caroline Litchfield

executive
#10

Thanks, Vamil, for that question. About the timing benefits we saw this quarter, let me lay out the complete picture, WINREVAIR included, so everyone has it: in the third quarter we saw a benefit of $550 million stemming from the timing of purchases. Of that amount, $200 million is tied to KEYTRUDA, and we expect it to fully unwind in the fourth quarter. $50 million is tied to WINREVAIR, which we also expect to unwind in the fourth quarter. Another $300 million is tied to our vaccines business, mainly GARDASIL. Of that, we expect $50 million to unwind in the fourth quarter, with the remaining $250 million unwinding in 2027.

Dean Li

executive
#11

Absolutely. Vamil, I appreciate the question. I'll break my response into two parts. First, I want to emphasize that for PAH Group 1 — not Group 2 — the field is progressively shifting toward the idea of remission with an activin signaling inhibitor. You've observed this in the European guidelines that have been released, and we hope a comparable standard will be adopted. This matters greatly because it implies that, akin to ACE inhibition in left heart failure, in this right heart failure with PAH Group 1, physicians in the field can approach the treatment paradigm differently. The reason I raise this is that you've now asked me about Group 2, which is a heart failure study. We have the CADE study. And regarding what we'll be doing in the CR study, I want to be quite clear: we are not broadening the patient population in any meaningful way. There are specifics concerning how we'll carry out the trial, but we genuinely believe this patient population observed in the CAN has an extraordinarily high unmet need. No approved treatment exists. The prognosis is really poor, and it's also an orphan indication. So from the cadence, we met primary endpoints — reduction in PVR — and important secondary endpoints. And we're going to launch the Phase III course this year with a 0.3 milligram per kilogram dose and with time to clinical worsening in the endpoints; and we enroll — we expect this will be a very attractive trial for patients with Group I pulmonary hypertension.

Michael Yee

analyst
#12

Dean, I'd like to add something to that point. ESMO was clearly an extremely active conference. Would you mind giving your perspective on the fact that you now feel more confident that China studies will be replicated more broadly across all of your global TroFuse studies? And given that I think lung cancer has had sufficient coverage, maybe you could just say which one or two other sac-TMT indications you see as most noteworthy and that perhaps people aren't focusing on.

Dean Li

executive
#13

All right; I had trouble hearing you, but I think what your question comes down to is the TroFuse ADC we have, our sac-TMT. I'd like to refer back to what we mentioned in the prepared remarks: our strategy has always consisted of two parts. First, we understood when entering this field that two TroFuse products were ahead of us, yet we were genuinely surprised they didn't move swiftly into indications beyond breast and lung — we saw that as a huge opportunity. You can see that reflected in our clinical trials, since we've advanced very quickly outside of lung and breast. We do have trials in lung and breast, but our movement beyond those has been rapid. The latest TroFuse-005 really demonstrates this. Why does that matter? Because TroFuse-005 can serve as proof. I'd point you to a presentation—I believe it was from 2025 or 2026—involving MK-2870 to 001, or Kelun-264 to 01. That was the Phase I/II endometrial cohort, and it gave us the informative data from China that helped us determine how to carry that over into TroFuse-005. So the key takeaway: that close collaboration with Kelun—it's not as though the translation will be exact—but it provides the signal for how you might translate it globally. That makes us confident the Kelun data is a truly meaningful signal for us, and that we can carry it over into the global trials. We also hope to reproduce that result in indications beyond lung and breast. Still, as Marjorie and Elliot have said lately, we intend to move quite aggressively in lung.

Brian Foard

executive
#14

At this point, one Dutch ruling stands. As Rob mentioned, we don't disagree with the Dutch court, and we'll keep working to get this overturned. So for the time being, we won't supply in Italy, Denmark, the Netherlands, France, Belgium, and Ireland. Broadly speaking, these are smaller-volume markets, so it's immaterial when it comes to our total subcu volume; but again, since we have longer IP, if we were to turn this decision positive, we'd have time to come back and make this convenient formulation available to patients in these markets as well. So on the whole, we feel we're in a really good place when it comes to subcutaneous adoption and the trajectory of where we want to be.

Akash Tewari

analyst
#15

Sounds like the main endpoint for your KRAS G12C first-line NSCLC study was switched from PFS and OS to just PFS back in September, and that reduced your enrollment target and pulled your primary completion earlier. Do you see that as part of a broader stance the FDA might be taking — where showing OS matters, but it isn't a gate for the initial filing? And how might that carry over to the design of your first-line sac-TMT PD-1 VEGF bispecific trial that you plan to begin in the first half of next year?

Dean Li

executive
#16

Yes. Thanks so much for bringing up calderasib. Let me just back up a bit so that others listening understand that this is our KRAS G12C inhibitor. We regard MK-1084, or calderasib, as a very important molecule. It has the profile we'd want any RAS molecule to have; it's extremely potent. It's extremely selective, and it combines well, for instance, with KEYTRUDA in the lung setting and with something like cetuximab in the CRC, and we've observed really strong data. Regarding our — as we move forward on this, I think some of it comes from discussions and feedback with the FDA. I do believe all of those endpoints will matter. PFS, OS eventually will all matter. But yes, we're moving with speed and rigor to get this calderasib into first-line lung with KEYTRUDA, but particularly subcu KEYTRUDA, moving quite fast. I should also stress that there's a difference in how we might approach clinical development philosophically versus others in this space. And for us, what really matters is, again, this is a spot where we're thinking about KEYNOTE-189, KEYNOTE-407 and asking ourselves, well, how do we displace that for those patients who have a KRAS G12C mutation, which is the dominant mutation for RAS in that patient population; and our strategy isn't to add it on top of pembro plus chemo, but to use a pembro plus that inhibitor by itself without the chemo, so that we can create a chemo-free option for patients.

Peter Dannenbaum

executive
#17

Great. Thanks Akash. Next question please.

Daina Graybosch

analyst
#18

I've got a follow-up question about RAS. There are 2 other RAS assets in your portfolio, including one you licensed from China. I was wondering, Dean, if you could take a step back and share your thinking on the whole portfolio across indications and combinations past calderasib.

Dean Li

executive
#19

Yes. Thank you so much for asking that. I'd say there are a lot of similarities here. Our interest in, say, KRAS G12D comes down to whether we could, for instance, replicate what we see with KRAS G12D in lung using a very similar strategy. But as I mentioned, calderasib and 1084 serve as our way of gauging what we do. . Another area where we believe we have pretty good data is calderasib with respect to CRC, particularly first-line CRC. Now with calderasib in CRC, KRAS G12C is a really important target, but it's the minority. It's the clear minority of RAS mutations, while KRAS G12D is the more dominant mutation, so our hope is that this KRAS G12D — for which we should have important clinical data in roughly the next year — will replicate what we've accomplished with KRAS G12C in, for example, lung and CRC. And obviously we'd also want to see what it does in pancreas; but our focus has been on how we use calderasib and how we examine the other isoforms of RAS, or the other subtypes of RAS, and how to recreate what we believe is a really good profile for KRAS G12C and how we replicate it for the other subtypes.

Peter Dannenbaum

executive
#20

Great. Let's take the next question, please.

Mohit Bansal

analyst
#21

Congratulations on the progress — on all of it. I just want to shift over to TL1A, or tulisokibart. It really does seem as though the IBD field is heading toward combinations as we attempt to push remission rates higher in earlier lines of treatment. Against that backdrop, how are you thinking about putting together a combination strategy for TL1A? Do you feel it's strategically necessary to own all the complementary mechanisms internally? Or would you be fine partnering with some established marketed products at this stage to identify the best combination?

Dean Li

executive
#22

Yes. Your line broke up a bit, so I'll respond somewhat generally, since I believe the question you're raising is a broader one in immunology — namely, how should one think about combinations and so forth. Combinations have been pursued a fair amount in immunology. They were pursued, I believe, in the 2018 — I can't recall, 2020 range. And by and large those combinations haven't delivered all that much benefit; so you don't see that combination strategy panning out. I do have to credit a company that more recently has advanced combinations of a sort, and we'll see how their data come through. But the bottom line is that combinations could matter. We believe combinations, for instance, in oncology truly matter. We think combining different mechanisms in ophthalmology truly matters, and combinations could truly matter across immunology. Still, I think every indication and each of the compounds out there will have to play out, and all of us as a field will have to do the work to establish just how important and how effective combination therapies are across immunology and the various indications.

Robert Davis

executive
#23

And maybe I would just add, since I think your question also had a business development angle to it: to start with, we have multiple assets advancing through early development internally. So we in fact have a variety of in-house assets that might serve as possible combination partners, but we're also still open on the business development side, regarding both products in development and commercialized products. So we're examining every avenue and stay confident that we're positioned to act depending on how we see the field evolve, as Dean said.

Peter Dannenbaum

executive
#24

Thank you, Mohit. Next question please, Julie. .

Steve Scala

analyst
#25

Could you tell me the volume LIPFENDRA moved in the quarter and how many prescriptions arrive as free drug? Despite a crowded field of competitors, Lipitor generated over $800 million during its initial 12 months on the market. I can't think of any reason why LIPFENDRA wouldn't do at least as well, and I'd like to hear whether you share that view.

Robert Davis

executive
#26

Appreciate the question. As we mentioned in the opening remarks, and as Caroline laid out, our focus is on affordability and access — that's the way we've structured this — so we're leaning on couponing plus other tactics. Brian will take that. What you ought to be seeing right now is that the script data appears quite robust. We're not disclosing specifics of our revenue guidance at this point, though Brian may be able to add some color so you get a sense of how we expect scripts to trend. By the end of 2027, we anticipate 30%-40% adoption in the United States.

Brian Foard

executive
#27

Absolutely, Steve — I appreciate the question. It seems your excitement about this area mirrors our own; the early positive response we're seeing is truly encouraging. I'll walk through a few of the figures. While we understand this is a marketplace, considerable inertia exists. We indicated the ramp would be gradual as prescriptions arrive, but let me offer a couple of metrics for you to consider: during the third quarter, we recorded upwards of 11,000 prescriptions, generated by more than 6,500 prescribers. The prescriber base is diversifying—not only cardiologists but general practitioners too, which is genuinely encouraging. Perhaps even more promising is that we're starting to see expansion beyond the PCSK9 space. Most scripts are being written for patients who are on other lipid-lowering background therapies, not for people switching from an injectable PCSK9—precisely the outcome we were hoping for. Keep in mind that, as Rob noted, sampling and coupon programs are currently in place, and those will have a short-term impact on revenue. At the same time, we're in active conversations with payers, with the aim of securing access as quickly as we can. On the commercial side, as we noted earlier, we anticipate broad access coverage in the commercial segment around 2027; and for Medicare, that actually comes in the 2028 timeframe as well. Our teams are now working very diligently to speed that up and pull it forward. But as we've said, this is an area where the marketplace has natural inertia. So we're cautious about early uptake, though the early signs look positive to us, and again, as we've said, we view this as a meaningful growth driver for us going forward — a multibillion opportunity.

Peter Dannenbaum

executive
#28

Thank you, Steve. Next question please, Julie.

Umer Raffat

analyst
#29

Dean, I've been mulling over the melanoma results that came out not long ago for the cancer vaccine. What I'd like to know is this: for patients with fewer neoantigens, how does that efficacy figure look, and maybe even more significantly, what about those whose tumors didn't carry a major driver mutation like NRAS or BRAF, and so on? I'm simply trying to reason through what that means for the RCC readout that's coming up.

Dean Li

executive
#30

Right. I'd prefer to stay a bit careful about racing ahead of the data that was shown and the data we're currently looking at and will probably share at some point — I believe some folks have mentioned roughly within the coming year. I don't want to get ahead of things. But let me stress — and if you'll indulge me, I'll spend a moment on this — Moderna hosted a press conference, or an investor meeting. I want to mention the two truly significant experts they had there: Georgina Long, who played a key role in this trial, and Antonio Ribas. I bring this up because I've come across some reports about melanoma and all of that. Let me simply note that Georgina Long served as a senior investigator for NADENA, and Antonio Ribas was the senior author of SWOG-1801. To start, I’ll share Antonio Ribas’s words: he called this a landmark in cancer drug development. We’re therefore keen to bring it before the FDA. I genuinely believe that, as those regarded as scientific leaders have interpreted the data, this trial stands as a landmark study in its own right. Given that, we would anticipate — or rather, we would hope — that once approved, NCCN guidelines might establish this as a new standard of care; that addresses the melanoma question. The remaining question concerns melanoma itself — within melanoma, TMB can span a spectrum. But overall, the TMB range in melanoma is simply shifted — shifted entirely toward higher TMB. So I'd be somewhat careful about reading too much into any data, say, for lower TMB in melanoma as though it signaled something for RCC. I think the core point is that what you've observed is that, at least in our experience, checkpoint inhibitors and IO agents — not only ours, but also things like IL-2 — have been effective. That's an area where RCC has been a favorable tumor relative to what you'd term immunoresponsive. And I think TMB matters, but I also believe TMB isn't the sole factor determining immune responsiveness. Looking at it that way is exactly how I'm approaching the RCC trial we have coming up. Whether TMB is broken out within melanoma doesn't really strike me as something that would make me more or less confident about how it relates to RCC.

Peter Dannenbaum

executive
#31

Thanks, Umer. Let's take the next question.

Asad Haider

analyst
#32

Many of mine have already been covered, but perhaps a broad, high-level one for you, Rob. Given everything that's happened throughout this year, it would be helpful to hear any refreshed perspective on that $70 billion revenue opportunity you've mentioned for the mid-2030s. Clearly, you've had a great deal of pipeline success during the year. The company keeps reshaping its portfolio. Things are heading the right way toward de-risking that figure. So maybe just unpack the positive and negative forces that have come into play affecting it, and remind us what wasn't factored into that outlook, what has positively surprised you, and what remains underappreciated.

Robert Davis

executive
#33

Yeah. No, I'm grateful for that. Honestly, taking a step back, the pride I have in what this company has achieved and in the way we're moving forward — especially since such a large share of our clinical data has come out positive so far. Of course, these are trials; each one is a fresh card, and you have to wait to see how the next card turns over. Still, what we've observed up to now leaves me very confident — more confident than before — about that $70 billion. As we mentioned, we now anticipate increasing that figure—both due to our confidence in what we currently have and because of elements that weren't factored in, which I believe ties into your question. I'd also point out that the Turns acquisition wasn't part of things when we provided that figure. It will add to that total. Beyond that, we essentially included nothing for the PD-1 VEGF, and based on what you've been hearing from multiple conferences and other meetings, our confidence keeps growing in it as a combination agent for us, particularly when we consider it alongside sac-TMT and everything else. There's clearly a lot of enthusiasm around this. As for sac-TMT, it will likely cover more indications down the road, since we're launching additional trials for it. And finally, and this matters a great deal, intismeran. Intismeran was part of what we originally anticipated, but that assumption rested on a product profile that — honestly, based on the data we've now seen — we believe will be commercially stronger than we had projected. So the target product profile is now more robust, and that by itself should generate some upside. Taking the portfolio as a whole, I feel quite confident about our position and our capacity to manage through the KEYTRUDA LOE. What matters here is that additional catalysts are on the way when you look ahead across the coming 12 to 24 months. So while I believe we still need those cards to play out, I'm feeling quite confident about the position we hold today.

Terence Flynn

analyst
#34

Great. Perhaps a follow-up to something asked earlier. Dean, I hear what you said about melanoma and its relevance to other tumor types. But what about the implications of the INT PDAC poster presented at ESMO? Could you help put that in context for us, and explain its importance as you think about other tumor types?

Dean Li

executive
#35

Yes; so I didn't get to enjoy the balmy weather in Spain, and I had Elliot and Marjorie out there. But I listened very carefully to some of the questions put to them and also to our Moderna colleagues. So I'll just answer in a broader way. We've got, let's say, four Phase III INTerpath trials along with five Phase IIs. Our plan is to expand beyond melanoma into lung, bladder, and RCC, staying within the conservative framework of areas we know to be immune responsive—and more specifically, responsive to our checkpoint inhibitor, and even more specifically to KEYTRUDA in the early-stage setting. Looking at our trials, I think this point matters a great deal, since people have raised various questions. I'll address your pancreatic study shortly, but we've clearly mapped out what it could achieve without an IO agent. That's exactly what you're seeing with INTerpath-014 in stage non-small cell lung cancer, and in NMIBC we're testing it without a checkpoint inhibitor. We're looking into the metastatic setting — that means first-line melanoma, which is INTerpath-012, along with first-line squamous non-small cell lung cancer, which is INTRPath-013. To address your specific point about something like IOrespons — that isn't where the bulk of our Phase III and Phase II work sits, though data coming from others in the field indicate we ought to examine it. So we're testing whether, together with a checkpoint inhibitor or IOrespons tumors, that's the right way to approach it. I'd also like to be sure everyone grasps that there were questions regarding perioperative treatment and all of that in melanoma. We have perioperative questions as well. In melanoma, that question isn't coming up as much for us, though it does arise in non-small cell lung cancer, which is INTRPath009. I wanted to convey a sense of some of the questions I've come across. We don't have all the trials, but hopefully this gives you a general picture: we have melanoma, we're working to expand the scope, and we're running experiments that will teach us not only which tumor type but also how to approach the indication and the mechanism of action.

Peter Dannenbaum

executive
#36

Thanks, Terence. We realize everyone has a packed schedule today, and we've hit the top of the hour, so this is where we'll wrap up. We appreciate all the excellent questions, and if anything else comes up, please reach out to the IR team.

Operator

operator
#37

Thank you for your participation. You may disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.